Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Natera investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $NTRA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) investors concerning the Company's possible violations of the federal securities laws. On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 percent of the time, and that patients who receive a positive result are s

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

AUSTIN, Texas, Jan. 3, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that its personalized molecular residual disease (MRD) test, Signatera, was selected as a winner in the Fierce Innovation Awards: Life Sciences Edition 2021, an awards program reviewed by an expert panel of judges and hosted by the publisher of Fierce Biotech and Fierce Pharma. The competition highlights companies with innovative technologies and solutions that have the potential to make the greatest impact for biotech and pharma companies.

Signatera™ Wins Fierce Life Sciences Innovation Award

Look for surprise values in underpriced stocks. Not the story issues being bally-hooed by touts and the media – everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths.

Natera: Standout Buy In Diagnostic Testing Materials, Now Seen By Market-Makers

Illumina

10X Genomics

Understanding the State of the Genomics Market

Red-Hot Genomics Plays With Google-Like dominance

AUSTIN, Texas, Dec. 9, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest findings presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December 7-10, 2021. Natera is presenting two studies based on the use of Signatera in high-risk breast cancer patients.

Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021

AUSTIN, Texas, Nov. 19, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG). This publication describes the performance of the Panorama non-invasive prenatal test (NIPT) for common trisomies.

Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)

AUSTIN, Texas, Nov. 11, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing, today announced that the CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using its Signatera molecular residual disease (MRD) test. An accompanying Billing and Coding Article, linked here , specifies that serial testing with Signatera is now covered for Medicare patients being treated with immunotherapy, regardless of tumor type.

Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test

Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product revenues. Product revenues rose 62% to $150.7 million.

Natera Raises FY21 Sales Outlook After Mixed Q3 earnings

Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2021 Results - Earnings Call Transcript

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated total revenues of $158.1 million in the third quarter of 2021 compared to $98.1 million in the third quarter of 2020, an increase of 61.1%.

Natera Reports Third Quarter 2021 Financial Results

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Natera (NTRA) Ahead of Earnings?

Naturally Splendid Enterprises Ltd said it has begun installing a new state-of-the-art, automated packaging system at its existing 20,000 square foot food manufacturing facilities, in order to package NATERA plant-based products for the retail markets, food service, and web sales. The company noted the versatile packaging system was selected for the array of products and packaging types it is designed to process, thus optimizing the opportunity to penetrate multiple channels.

Naturally Splendid installs new packaging system to boost NATERA plant-based product distribution

AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today announced the initial results1 from the global, multi-site, prospective Trifecta study led by Phil Halloran, M.D., Ph.D., director, Alberta Transplant Applied Genomics Centre.

Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study

The mean of analysts' price targets for Natera (NTRA) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Natera (NTRA) Could Rally 27%: Here's is How to Trade

AUSTIN, Texas, Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2021, after the market close on November 4, 2021. Natera will host a conference call and webcast at 1:30 p.m.

Natera Announces Third Quarter 2021 Earnings Conference Call

Naturally Splendid Enterprises Ltd has announced that its selection of Natera Plant-Based foods was featured at the British Columbia Institute of Technology (BCIT), which was promoting a Meatless Monday event. The Vancouver, British Columbia-based company said its selection, featured at BCIT on October 18, 2021,  included chick-un cutlets, sweet chili chick-un tenders, and chick-un nuggets.

Naturally Splendid says Natera plant based foods featured at BCIT Meatless Monday

AUSTIN, Texas, Oct. 18, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, announced the launch and availability of its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transplant recipients. The launch represents the latest addition to Natera's transplant monitoring portfolio beyond kidney and heart transplantation.

Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test

AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer (CRC). The full study can be found here.

Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management

AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cfDNA) testing, announced the completion of the VALID Study (Validation for Allograft Lungs Implementing Donor-derived cell-free DNA) for Prospera™ in lung transplant recipients. This clinical validation study has been accepted as a late-breaking abstract for presentation at the American College of Chest Physicians (ACCP) international online meeting, CHEST 2021, to be held on October 17–20, 2021.

Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation

Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Burkes Michael Brophy exercised options to purchase 2,292 Natera shares for $0 on September 28.

Notable Natera Insider Trades $3M In Company Stock

AUSTIN, Texas, Sept. 29, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), is pleased that the Delaware Federal District Court ruled today that all three patents CareDx has asserted against Natera "are invalid as a matter of law under §101 for claiming patent-ineligible subject matter.

Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents

The stock price of Natera, a clinical genetic testing company, has seen a 14% rise over the last twenty-one trading days, while it is up 30% year-to-date. The recent rise in the stock can be attributed to the company's launch of its Prospera heart transplant assessment test.

What's Next For Natera Stock After A 14% Rise In A Month?

Rowan Chapman, at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 17, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Rowan Chapman exercised options to purchase 5,500 Natera shares at a price of $32.15 per share for a total of $176,825 on September 17.

News for Natera Stock (NTRA)